• Most Popular
  • Most Shared

Bayer unit sues Abbott over Humira arthritis drug

Wed Dec 31, 2008 12:32am EST

Stocks

   

Dec 31 (Reuters) - Bayer Healthcare LLC, a unit of Bayer AG BAYG.DE filed a patent-infringement lawsuit in a U.S. court against Abbott Laboratories (ABT.N) relating to the drug Humira, Abbot's top-selling product.

Stocks  |  Regulatory News  |  Global Markets

In a suit filed on Dec 24 in the U.S. District Court for the Eastern District of Texas, Bayer Healthcare said Abbott's drug infringes on a 1997 Bayer patent "Human Anti-TNF Antibodies." The patent covers antibodies that fight a protein called "tumor necrosis factor" (TNF), that causes inflammation.

Bayer Healthcare asked the court to determine that Abbott infringed on the patent and to award damages, the court filing showed.

Abbott could not be immediately reached for comment.

Humira is used to treat certain patients with arthritis, psoriasis, Crohn's Disease and a form of arthritis called ankylosing spondylitis. (Reporting by Ajay Kamalakaran in Bangalore; Editing by Kim Coghill)

Stocks
Regulatory News
Global Markets


More from Reuters

Photo

U.S. probing if al Qaeda linked to airplane incident

WASHINGTON (Reuters) - The United States is investigating whether al Qaeda was involved in a Christmas Day attempt to blow up a passenger jet, but there is no early evidence the Nigerian suspect in the case was part of a larger plot, the U.S. homeland security chief said on Sunday. | Video

» More Top News
A Delta Airbus 330 airliner sits on a runway at Detroit Metropolitan Airport in Romulus, Michigan in this video grab made December 25, 2009. Credit: REUTERS/WDIV TV/Handout

The battle in mid-air

The attraction of bombing airliners means the aviation industry has to be constantly vigilant in its fight against attackers.  Full Article 

U.S.
A caution sign is seen next to a stock board at the Australian Securities Exchange (ASX) in Sydney September 5, 2008. REUTERS/Daniel Munoz
Political Risk in 2010:

Don't say we didn't warn you

With the financial crisis (mostly) in the past, U.S. investors are eying a fresh start to the coming year. Here's a look at what speedbumps lie ahead.  Full Article 

Global Markets